pramlintide vs repaglinide
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of pramlintide and repaglinide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics Drugs That May Decrease the Blood Glucose Lowering Effect of Repaglinide Intervention: Repaglinide dose increases and increased frequency of glucose monitoring may be required when co-administered.
Symlin
Prandin
Symlin is a drug that helps control blood sugar in people with type 1 or type 2 diabetes who also use insulin. It works with insulin to lower blood sugar levels after meals.
Repaglinide (Prandin) helps control blood sugar in adults with type 2 diabetes. It works best when used with diet and exercise.
Symlin is used to help manage blood sugar levels in adults with type 1 or type 2 diabetes. You should already be using insulin at mealtimes. This medicine is for people whose blood sugar is not well-controlled, even with the best insulin treatment.
Repaglinide is used to lower blood sugar in adults with type 2 diabetes. It should be used along with a healthy diet and regular exercise. This medicine is not for people with type 1 diabetes or diabetic ketoacidosis.
Symlin is similar to a natural hormone in your body. It slows down how quickly food leaves your stomach. It also helps to prevent your liver from releasing too much sugar after you eat, and reduces your appetite.
Repaglinide helps your pancreas release insulin after you eat. Insulin helps move sugar from your blood into your cells. This lowers your blood sugar levels.
- • Nausea
- • Vomiting
- • Loss of appetite
- • Headache
- • Fatigue
- • Low blood sugar
- • Upper respiratory infection
- • Headache
- • Sinus infection
- • Joint pain
- High blood sugar 15
- Sudden kidney damage 11
- Long-term kidney disease 11
- Feeling sick to your stomach 9
- Shortness of breath 8
- Hypoglycaemia 765
- Acute Kidney Injury 548
- Drug Interaction 418
- Diarrhoea 365
- Lactic Acidosis 364
Symlin can cause very low blood sugar, especially if you have type 1 diabetes. This can happen within 3 hours after a Symlin shot. To avoid this, follow your doctor's instructions carefully and check your blood sugar often. Make sure you know the signs of low blood sugar.
Repaglinide can cause low blood sugar (hypoglycemia). If you skip a meal, skip your dose of repaglinide to avoid low blood sugar. Do not use repaglinide with NPH-insulin. There is no proof that repaglinide lowers your risk of heart problems.
It is not known if Symlin will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Symlin passes into breast milk, so discuss breastfeeding with your doctor.
Tell your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Repaglinide is not recommended while breastfeeding due to the risk of low blood sugar in the baby.
Also Compare, Nearby Drugs
Compare repaglinide with
How to Read This pramlintide vs repaglinide Comparison
pramlintide is classified in the Amylin Analog drug class, while repaglinide sits within the Meglitinide class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, pramlintide has 54 submissions while repaglinide has 2,460. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to based on the provided text, pramlintide may decrease the blood-sugar-lowering effect of repaglinide. this can result in blood sugar levels that are higher than your target range.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for pramlintide or repaglinide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.